GNLX CIK: 1231457

GENELUX Corp

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
(positive)
millions USD
FY21:
–
FY22:
–
FY23:
–
FY24:
–
FY25:
–
(positive)
Change from FY21 to FY25
millions USD
FY21:
−14.6
FY22:
−3.01
FY23:
−24.2
FY24:
−31.7
FY25:
−33.2
(positive)
Change from FY21 to FY25
millions USD
FY21:
−14.1
FY22:
−2.05
FY23:
−26.1
FY24:
−29.3
FY25:
−32.6
(positive)
Change from FY21 to FY25
millions USD
FY21:
−16.4
FY22:
−4.11
FY23:
−28.3
FY24:
−29.9
FY25:
−32.1
(positive)
Change from FY21 to FY25
millions USD
FY21:
−16.4
FY22:
−5.21
FY23:
−28.3
FY24:
−29.9
FY25:
−32.1

All amounts in millions USD FY21: figures supplemented from Twelve Data because the SEC filings do not reach back this far. Data sources:SEC EDGARTwelve Data